Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ACP3 | P15309 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377382 | 0.86 | HSD17B10 (0.43) | ITGB3ITGA2BCHRM2CHRM1CHRM3 | |
| SCHEMBL19406960 | 0.82 | ITGB3 (0.41) | ITGB3ITGA2B | |
| SCHEMBL19377385 | 0.77 | HSD17B10 (0.43) | ITGB3ITGA2BCHRM2CHRM1CHRM3 | |
| SCHEMBL19377377 | 0.76 | ITGB3 (0.46) | ITGB3ITGA2BPOLB | |
| SCHEMBL19377141 | 0.75 | JAK3 (0.46) | ITGB3ITGA2B | |
| SCHEMBL19377140 | 0.73 | ROCK2 (0.46) | HSD17B10 | |
| SCHEMBL19377374 | 0.67 | ITGB3 (0.46) | ITGB3ITGA2BPOLB | |
| SCHEMBL19377036 | 0.67 | HSD17B10 (0.42) | ITGB3ITGA2BHSD17B10L3MBTL1 | |
| SCHEMBL19377136 | 0.66 | JAK3 (0.46) | ITGB3ITGA2B | |
| SCHEMBL19377032 | 0.63 | HSD17B10 (0.42) | ITGB3ITGA2BHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | ITGB3 4595/4885ITGA2B 4377/4885CHRM2 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.